Stocks Health care AORT
NYSE · Health careArtivion, Inc. (AORT)
Artivion, Inc. brought in $481.9M of revenue over the twelve months to September 30, 2026, up 14.0% from a year earlier. It posted a net loss of $17.6M. Operating cash flow minus capital spending left $839K of free cash flow in fiscal 2025. At September 30, 2026 it held $48.4M in cash against $363.8M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 6, 2026.
Key facts about Artivion, Inc.
- Net worth
- Artivion, Inc. has a market value (market cap) of $1B at the latest share price, and shareholders' equity of $446.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $441.3M (+13.6% year on year), with net income of $9.8M. Over the 12 months to September 30, 2026: revenue $481.9M, net loss $17.6M.
- Cash flow
- In fiscal 2025 operations brought in $39.9M of cash; after $39M of capital spending, free cash flow was $839K.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 6, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Artivion, Inc.'s next report is expected around February 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Artivion, Inc. does
Artivion, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NYSE under the ticker AORT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $441.3M | $9.8M | $0.21 | $839K |
| 2024 | $388.5M | -$13.4M | -$0.32 | $11M |
| 2023 | $354M | -$30.7M | -$0.75 | $9.1M |
| 2022 | $313.8M | -$19.2M | -$0.48 | -$15.9M |
| 2021 | $298.8M | -$14.8M | -$0.38 | -$15.7M |
| 2020 | $253.2M | -$16.7M | -$0.44 | $5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where AORT ranks in Health care
Dividends
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2019 | $0.00 | n/a | n/a |
| 2018 | $0.00 | n/a | n/a |
| 2017 | $0.00 | n/a | n/a |
| 2016 | $0.00 | n/a | n/a |
| 2015 | $0.12 | $3.4M | n/a |
| 2014 | $0.12 | $3.3M | n/a |
Latest SEC filings
What Artivion, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 9.2% to $123.8M versus the same quarter last year; diluted EPS -$0.16 versus $0.13.
- November 5, 2026
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 11% to $125.8M versus the same quarter last year; diluted EPS -$0.28 versus $0.03.
- August 6, 2026
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- May 21, 2026
- May 18, 2026
- May 15, 2026
What is AORT worth? A DCF from its reported cash flow
Insider trades
What the people running Artivion, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $2.6M worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 10, 2026 | Green Andrew MSVP, Regulatory and Quality | Sold | 11,480 | $286.7K |
| September 3, 2026 | Green Andrew MSVP, Regulatory and Quality | Sold | 1,493 | $38.8K |
| September 2, 2026 | Green Andrew MSVP, Regulatory and Quality | Sold | 6,510 | $177.5K |
| August 19, 2026 | Mackin James PPresident & CEO | Sold | 70,000 | $2M |
| August 14, 2026 | Berry Lance AEVP, COO, CFO & Treasurer | Sold | 715 | $20.4K |
| August 14, 2026 | Green Andrew MSVP, Regulatory and Quality | Sold | 616 | $17.6K |
| August 12, 2026 | Holloway Jean FSVP, General Counsel | Sold | 977 | $27.8K |
| June 11, 2026 | Green Andrew MSVP, Regulatory and Quality | Exercised options | 14,001 | $258.2K |
Who owns AORT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| BlackRock, Inc.13G, passive | 14.7% | October 27, 2026 |
| Nomura Asset Management International Inc.13G, passive with 1 related filers | 6.5% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 206 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 6,674,017 | +199,163 |
| Nomura Asset Management International Inc. | 3,184,974 | +728,828 |
| Morgan Stanley | 2,557,961 | +288,667 |
| Juniper Investment Company, LLC | 2,019,885 | +830,749 |
| Vanguard Capital Management LLC | 2,004,619 | +52,611 |
| Fmr LLC | 1,963,471 | -619,956 |
| State Street Corp | 1,858,051 | +175,778 |
| Ophir Asset Management Pty Ltd | 1,800,008 | +849,158 |
| Perceptive Advisors LLC | 1,737,290 | +100,000 |
| Conestoga Capital Advisors, LLC | 1,623,700 | +448,290 |
| Wellington Management Group Llp | 1,260,279 | +103,592 |
| Geode Capital Management, LLC | 1,114,297 | -18,206 |
| Silvercrest Asset Management Group LLC | 1,024,091 | +363,150 |
| Vanguard Portfolio Management LLC | 988,219 | -49,226 |
| Dimensional Fund Advisors LP | 947,941 | -79,634 |
| Citadel Advisors LLC | 827,594 | +756,725 |
| First Eagle Investment Management, LLC | 693,146 | +381,545 |
| Yarger Wealth Strategies, LLC | 634,223 | 0 |
| Royce & Associates LP | 639,282 | +214,000 |
| Northern Trust Corp | 550,532 | +52,633 |
Insiders
15 insiders reported holding 2,470,153 shares in total, about $51M at the last price.
| Holder | Shares |
|---|---|
| Mackin James PPresident & CEO | 877,275 |
| Davis John EChief Commercial Officer | 230,794 |
| Berry Lance AEVP, COO, CFO & Treasurer | 210,112 |
| Holloway Jean FSVP, General Counsel | 184,118 |
| Bevevino Daniel JDirector | 157,637 |
| Ackerman Thomas FDirector | 157,472 |
| Horton AmyVP, Chief Accounting Officer | 139,088 |
| Salveson Jon WDirector | 137,416 |
| Bullock JamesDirector | 76,223 |
| Burbank Jeffrey HDirector | 61,372 |
Questions about AORT
What does Artivion, Inc. do?
Artivion, Inc. is a company in the Health care sector, listed on NYSE as AORT. Its shares trade on NYSE under the ticker AORT.
What is Artivion, Inc.'s net worth?
Artivion, Inc. has a market value (market cap) of $1B at the latest share price, and shareholders' equity of $446.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Artivion, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $17.6M on revenue of $481.9M.
How much revenue does Artivion, Inc. make?
Over the twelve months to September 30, 2026 Artivion, Inc. reported revenue of $481.9M. That is 14.0% more than a year earlier.
When did Artivion, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 6, 2026. It covers the period to September 30, 2026.
When is Artivion, Inc.'s next earnings report?
Artivion, Inc.'s next report is expected around February 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare AORT with
Follow AORT
Get an email when Artivion, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Artivion, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.